What Serina Therapeutics does

Serina Therapeutics is a clinical-stage biotechnology company headquartered in Huntsville, Alabama, that develops polymer-modified small molecule therapeutics using its proprietary POZ Platform. The company was formed in March 2024 through the merger of a subsidiary of AgeX Therapeutics with the legacy Serina entity and now trades on NYSE American under ticker SER. Its core technology, POZylation, attaches a proprietary POZ polymer to small molecule drugs through multiple pendant groups, enabling controlled, sustained release via a single plasma enzyme and producing near-linear pharmacokinetics. This architecture is positioned to address known limitations of PEG-based polymers, which can elicit anti-polymer antibodies, while extending dosing intervals and reducing peak/trough drug level fluctuations.

The company's lead clinical candidate, SER-252 (POZ-Apomorphine), is a twice-weekly subcutaneous injection formulation of apomorphine targeting advanced Parkinson's disease. SER-252 is currently in a Phase 1b registrational trial under the 505(b)(2) NDA pathway, which allows reliance on FDA's prior findings for apomorphine. The first patient was dosed in Australia in February 2026, with additional U.S. sites planned, and Enable Injections is providing the enFuse wearable delivery platform as part of the combination product profile. A second pipeline candidate, SER-270, is also in development leveraging the POZ Platform for neurological indications.

Serina Therapeutics is pre-revenue and has no commercialized products. Its forward revenue model anticipates product sales and licensing following regulatory approval and commercialization, with ultimate customers being advanced Parkinson's disease patients and the healthcare providers who treat them. The company has funded operations primarily through private placement financings, raising approximately $5 million in April 2025, up to $20 million in milestone-based tranches beginning September 2025, and roughly $21.2 million in March-April 2026, including a $15 million first tranche led by investor Greg Bailey who became Co-Chairman. As of March 31, 2026, the company held $24.5 million in cash against a $6.9 million quarterly net loss, and faces NYSE American listing compliance challenges with stockholders' equity of $1.6 million, though the exchange has accepted a remediation plan with a July 2027 deadline.

Name

Serina Therapeutics

Legal name

Serina Therapeutics, Inc.

Website

https://serinatherapeutics.com

Company type

Public

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Serina Therapeutics is a clinical-stage biotechnology company developing polymer-modified small molecule therapeutics via its proprietary POZ Platform, with lead candidate SER-252 in Phase 1b registrational trials for advanced Parkinson's disease.

Ownership category

akta.pro rank

Product category

Polymer-based Neurological Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology/CNS Gene Therapies (HLAAACAH)

akta.pro secondary industry

Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)

Keywords

• Polymer drug delivery
• Parkinson's disease therapy
• Sustained release therapeutics
• Polymer drug optimization
• Subcutaneous injectable drugs

Headquarters

HQ city

Huntsville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel

Revenue model

1. Drug Development and Commercialization: Pre-revenue clinical-stage biotechnology company developing novel therapeutics for neurological diseases. The company is conducting Phase 1b registrational trials for SER-252 for advanced Parkinson's disease. Revenue will be generated through product sales upon regulatory approval and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Serina Therapeutics is a clinical-stage biotechnology company developing therapeutics using its proprietary POZ Platform polymer technology for precise, controlled, and sustained drug delivery. Its lead clinical candidate, SER-252 (POZ-apomorphine), is a twice-weekly subcutaneous injection in Phase 1b registrational trials for advanced Parkinson's disease, designed to provide continuous dopaminergic stimulation. The company also has a pipeline candidate SER-270 and is pursuing a 505(b)(2) NDA regulatory pathway.

Product overview

Serina Therapeutics is a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ Platform™ polymer drug optimization technology. The company's portfolio consists of lead clinical candidate SER-252 (POZ-apomorphine) for advanced Parkinson's disease currently in Phase 1b registrational trials, and pipeline candidate SER-270. The POZ Platform enables near-linear release kinetics through controlled, sustained drug delivery via subcutaneous injection, addressing limitations of traditional PEG-based polymers by avoiding immunogenic responses. The company is utilizing the 505(b)(2) regulatory pathway for SER-252 and has established partnerships with Enable Injections for drug delivery using the enFuse wearable platform.

Differentiator

Problem solved

Functional benefit

Brands

• POZ Platform: Proprietary polymer platform technology that enables precise, controlled, and sustained drug exposure through POZylation, improving how drugs perform in the body.
• POZ Platform™

Products and services

• SER-252 (POZ-Apomorphine) SER-252 is a POZylated version of apomorphine for advanced Parkinson's disease, delivered as a twice-weekly subcutaneous injection designed to provide continuous dopaminergic stimulation and maintain patients in an 'on' state 24/7. It uses the POZ Platform to enable sustained drug release with near-linear kinetics, potentially replacing complex pump-based infusion therapies.
• SER-270 SER-270 is a pipeline product candidate leveraging the POZ Platform technology for therapeutic applications, with development focus on neurological diseases.
• POZ Platform™ Proprietary polymer drug optimization platform that enables precise, controlled, and sustained drug exposure through POZylation technology, addressing limitations of PEG and other biocompatible polymers by avoiding immunogenicity while extending delivery intervals. Can be dosed via IV, SC, or IM routes to address a broad range of clinical indications.

Quantifiable outcome

• 10 million+ people worldwide living with Parkinson's disease
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Parkinson's AustraliacoreStrategic or Co-development Partner · 19 February 2026Partnership with Parkinson's Australia to support patient identification and enrollment for the Phase 1b registrational trial of SER-252 in Australia. The organization assists with clinical trial operations and patient recruitment for the Parkinson's disease study.
• Neuroscience Trials AustraliacoreImplementation/ SI/ Consulting Partner · 19 February 2026Clinical research organization partnership supporting trial operations in Australia. The organization provides site management and clinical trial support services for the Phase 1b trial evaluating SER-252 for advanced Parkinson's disease.
• Enable InjectionscoreStrategic or Co-development Partner · 19 January 2022Enable Injections provides its enFuse wearable drug delivery platform for use with SER-252 (POZ-apomorphine). The partnership enables a highly differentiated target product profile with potential for best-in-class treatment for advanced Parkinson's disease patients. The enFuse device allows subcutaneous injection delivery of the POZylated drug formulation.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Lundbeck: Lundbeck markets Apokyn (apomorphine subcutaneous injection), the reference listed drug for SER-252. As the established apomorphine player in advanced Parkinson's, Lundbeck is the most direct competitor Serina will face if SER-252 reaches the market.
• Acadia Pharmaceuticals: Acadia commercializes Nuplazid (pimavanserin) for Parkinson's disease psychosis, a CNS specialty pharma with a similar indication focus and specialty-pharma commercial model. It is the most directly comparable publicly traded Parkinson's-focused specialty biotech.
• Supernus Pharmaceuticals (with Adamas): Supernus acquired Adamas Pharmaceuticals and markets Gocovri, an amantadine-based therapy for Parkinson's dyskinesia. Comparable as a CNS specialty pharma with a Parkinson's product competing in the advanced-PD segment Serina targets.

Broad incumbents

• AbbVie: AbbVie markets Duopa (carbidopa/levodopa intestinal gel) and Vyalev (produodopa) for advanced Parkinson's disease, the dominant continuous-infusion standard-of-care Serina aims to displace with a twice-weekly subcutaneous injection.
• Sage Therapeutics: Sage Therapeutics is a clinical-stage and commercial CNS-focused biotech with novel small-molecule approaches to neurological diseases. Comparable as a publicly traded CNS specialty biotech with platform-based pipeline ambitions.

Regional players

• Mitsubishi Tanabe Pharma: Mitsubishi Tanabe Pharma markets apomorphine products in Japan and is developing a subcutaneous apomorphine infusion (APL-130277 licensing lineage). It is a regional incumbent competitor in the apomorphine space relevant to Serina's lead program.

Emerging players

• Praxis Precision Medicines: Praxis is a clinical-stage CNS biotech developing therapies for movement disorders and epilepsy, including Parkinson's disease. Comparable as a small-cap, CNS-focused emerging biotech with a similar capital structure and clinical-stage risk profile.
• Intec Pharma: Intec Pharma developed the Accordion Pill, an extended-release gastric-retentive drug delivery platform applied to levodopa for Parkinson's disease. Comparable as a small biotech applying novel drug-delivery technology to Parkinson's.
• Voyager Therapeutics: Voyager is a clinical-stage gene therapy company with CNS/Parkinson's programs. Comparable as a small-cap, public, clinical-stage CNS biotech with platform-based R&D and similar financing dynamics.

Others

• Enable Injections: Enable Injections is Serina's strategic partner and provides the enFuse wearable subcutaneous drug-delivery platform used with SER-252. Included as an adjacent enabler, since commercial uptake of SER-252 will depend on continued partnership with Enable's delivery technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/serina-therapeutics-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds11 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Serina Therapeutics